FRANK FLOCA: Open Payments
NPI 1962443382 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,729 in 100 payments from 13 companies in 2025. Trend: 2023 $6,575 · 2024 $11,406 · 2025 $2,729
Food & beverage: $2,729
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $646 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $574 |
| Otsuka America Pharmaceutical, Inc. | 17 | $374 |
| Teva Pharmaceuticals USA, Inc. | 17 | $287 |
| Vanda Pharmaceuticals Inc. | 13 | $286 |
| E.R. Squibb & Sons, L.L.C. | 6 | $210 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Janssen Pharmaceuticals, Inc | 5 | $92 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Alpha Cognition USA, Inc. | 1 | $36 |
Products named: CAPLYTA, ARISTADA, REXULTI, FANAPT, UZEDY, INVEGA SUSTENNA, COBENFY, LYBALVI.
Industry payments across TX — which companies pay providers there.
